Professor Jens Bedke: Pathological Response and Survival in KEYNOTE-866—Endpoints and Multidisciplinary Care in Muscle-Invasive Bladder Cancer
Assessing the value of perioperative treatment for muscle-invasive bladder cancer (MIBC) requires attention to both pathological response and survival outcomes. Delivering that treatment throughout the patient's journey also calls for close coordination between medical oncology and urology. At the 2026 European Society for Medical Oncology (ESMO) Congress, the phase 3 KEYNOTE-866 trial reported results for perioperative pembrolizumab combined with cisplatin-based chemotherapy in patients with cisplatin-eligible MIBC. In this interview, the trial's presenter, Professor Jens Bedke of Stuttgart, Germany, discusses the study design and key findings, the interpretation of pathological complete response (pCR) and survival endpoints, and multidisciplinary coordination across neoadjuvant therapy, radical cystectomy and adjuvant therapy.









